ColoMarker, a blood test for the early detection of colorectal cancer, has received CE Mark approval.
The test, developed by EDP Biotech, will initially be introduced to the 30 member states of the European Economic Area.
ColoMarker has been clinically tested in the United States. It has demonstrated 97 percent sensitivity, 86 percent specificity for colorectal cancer and a 48 percent detection rate of adenomatous polyps.
More articles on gastroenterology:
Are current endoscopy cleaning protocols enough?
Hudson Valley Hospital Center adds 2 gastroenterologists
HCV drug Sovaldi sales on the decline
The test, developed by EDP Biotech, will initially be introduced to the 30 member states of the European Economic Area.
ColoMarker has been clinically tested in the United States. It has demonstrated 97 percent sensitivity, 86 percent specificity for colorectal cancer and a 48 percent detection rate of adenomatous polyps.
More articles on gastroenterology:
Are current endoscopy cleaning protocols enough?
Hudson Valley Hospital Center adds 2 gastroenterologists
HCV drug Sovaldi sales on the decline